SESTINI, ROBERTA
 Distribuzione geografica
Continente #
NA - Nord America 5.204
EU - Europa 3.221
AS - Asia 1.740
SA - Sud America 180
AF - Africa 49
OC - Oceania 32
Totale 10.426
Nazione #
US - Stati Uniti d'America 5.167
RU - Federazione Russa 1.041
PL - Polonia 782
SG - Singapore 560
CN - Cina 378
IT - Italia 336
HK - Hong Kong 270
SE - Svezia 247
IE - Irlanda 238
VN - Vietnam 197
DE - Germania 162
BR - Brasile 136
KR - Corea 130
UA - Ucraina 115
FI - Finlandia 93
FR - Francia 83
GB - Regno Unito 64
IN - India 57
JO - Giordania 34
AU - Australia 31
TR - Turchia 25
CA - Canada 20
AR - Argentina 19
CH - Svizzera 17
JP - Giappone 16
BD - Bangladesh 13
CI - Costa d'Avorio 12
ID - Indonesia 11
NL - Olanda 11
ZA - Sudafrica 9
MX - Messico 8
CZ - Repubblica Ceca 7
ES - Italia 6
IQ - Iraq 6
SA - Arabia Saudita 6
BE - Belgio 5
EC - Ecuador 5
MA - Marocco 5
PE - Perù 5
UZ - Uzbekistan 5
CL - Cile 4
EG - Egitto 4
PK - Pakistan 4
TW - Taiwan 4
UY - Uruguay 4
VE - Venezuela 4
BJ - Benin 3
LT - Lituania 3
LY - Libia 3
MY - Malesia 3
NG - Nigeria 3
NP - Nepal 3
OM - Oman 3
SC - Seychelles 3
AT - Austria 2
CO - Colombia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
KE - Kenya 2
MD - Moldavia 2
NO - Norvegia 2
PH - Filippine 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AZ - Azerbaigian 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MN - Mongolia 1
MU - Mauritius 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
SN - Senegal 1
TH - Thailandia 1
TN - Tunisia 1
Totale 10.426
Città #
Santa Clara 1.096
Warsaw 782
Ashburn 569
Fairfield 481
Singapore 434
Chandler 300
Dublin 238
Woodbridge 236
Hong Kong 220
Seattle 205
Cambridge 185
Jacksonville 177
Houston 163
Wilmington 161
San Jose 144
Seoul 128
Beijing 115
Ann Arbor 93
Florence 71
Dallas 69
Buffalo 66
Princeton 64
Lawrence 59
Altamura 58
Ho Chi Minh City 57
Lauterbourg 55
The Dalles 55
Los Angeles 53
Hanoi 52
Munich 47
Boardman 46
Medford 40
Shanghai 37
Mumbai 36
Moscow 34
New York 34
Boston 33
Melbourne 30
Milan 27
Hefei 22
Helsinki 21
Dearborn 20
San Diego 20
Turku 19
Bern 17
São Paulo 16
Tokyo 16
Izmir 15
Kent 15
Abidjan 12
Norwalk 12
Phoenix 12
Redondo Beach 12
Brooklyn 11
Frankfurt am Main 11
Paris 11
Council Bluffs 10
Dong Ket 10
London 9
Orem 9
Rome 9
Chicago 8
Guangzhou 8
Haiphong 8
West Jordan 8
Auburn Hills 7
Bremen 7
Clifton 7
Montreal 7
Yubileyny 7
Atlanta 6
Da Nang 6
Frankfurt Am Main 6
Jakarta 6
Toronto 6
Brussels 5
Denver 5
Falls Church 5
Hillsboro 5
Johannesburg 5
Manchester 5
Miano 5
Pune 5
San Francisco 5
Secaucus 5
Shenzhen 5
Amsterdam 4
Andover 4
Campo Grande 4
Chions 4
Hải Dương 4
Kunming 4
Montevideo 4
Nanjing 4
Naples 4
Poplar 4
Quito 4
Stockholm 4
Tashkent 4
Tianjin 4
Totale 7.267
Nome #
NF2 mutation screening by denaturing high-performance liquid chromatography and high-resolution melting analysis 358
A Founder Effect for the HGD G360R Mutation in Italy: Implications for a Regional Screening of Alkaptonuria 345
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 328
Endothelin-1: a new autocrine/paracrine factor in rat testis. 318
A systematic assessment of accuracy in detecting somatic mosaic variants by deep amplicon sequencing: Application to NF2 gene 318
High resolution melting analysis for a rapididentification of heterozygous and homozygous sequence changes in the MUTYH gene 312
Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection 226
Broadening the spectrum of SMARCB1-associated malignant tumors: A case of uterine leiomyosarcoma in a patient with schwannomatosis 215
A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas. 214
PREMATURE OVARIAN FAILURE AND FRAGILE X PREMUTATION: A STUDY ON 45 WOMEN 208
A novel PAX1 null homozygous mutation in autosomal recessive otofaciocervical syndrome associated with severe combined immunodeficiency 206
Genetic insights into familial tumors of the nervous system. 198
Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. 196
Application of COLD-PCR for improved detection of NF2 mosaic mutations 192
Adenosine triphosphate release by osmotic shock and hemoglobin A1C in diabetic subjects' erythrocytes. 191
Expanding the mutational spectrum of LZTR1 in schwannomatosis. 187
Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma 182
Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide. 180
Phenotype variability of neural crest-derived tumours in six Italian families segregating the same founder SDHD mutation Q109X. 177
SDH mutations in patients affected by paraganglioma syndromes: a personal experience. 176
Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation 176
Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma. 175
The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy. 174
Tacrolimus causes reduced GLI1 expression and phenotypic changes in the TE 354.T basal cell carcinoma cell line. 172
Detection of rearrangements in the NF2 gene using semi-quantitative multiplex fluorescent PCR. 171
GENE AMPLIFICATION FOR c-erbB-2, c-myc, epidermal growth factor receptor, int-2 and N-myc MEASURED BY QUANTITATIVE PCR WITH A MULTIPLE COMPETITOR TEMPLATE. 171
Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. 170
NF2 mutation screening by denaturing high-performance liquid chromatography and high-resolution melting analysis. 169
Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors 169
The use of COLD-PCR and High Resolution Melting Analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer 168
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis 167
Detection of BRCA1 and BRCA2 variants in circulating free DNA by using a commercial kit 167
Multiple spinal ganglioneuromas in a patient harboring a pathogenic NF1 mutation. 163
Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique 160
Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. 160
Sonde di DNA con rivelazione in chemiluminescenza 158
An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. 158
Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. 156
Neurofibromatosis type 2 attributable to gonosomal mosaicism in a clinically normal mother, and identification of seven novel mutations in the NF2 gene. 152
MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. 150
Expression of GLI-1 and cytoplasmic and secretory proteins in a human basal keratinocyte cell line. 147
Schwannomatosis associated schwannomas show a different NF2 mutational spectrum compared to Neurofibromatosis type 2 patients 147
Triple synchronous cutaneous melanoma: a clinical, dermoscopic, and genetic case study. 141
A new and simple method for HLA-B*5701 screening before abacavir treatment 139
Malignant extra-adrenal pheochromocytoma caused by an SDHB intronic variation leading to a 54-bp deletion in exon 4. 136
Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations. 135
QUANTITATIVE POLYMERASE CHAIN REACTION-BASED HOMOGENEOUS ASSAY WITH FLUOROGENIC PROBES TO MEASURE C-ERBb-2 ONCOGENE AMPLIFICATION. 134
Measuring c-erbB-2 oncogene amplification in fresh and paraffin-embedded tumors by competitive polymerase chain reaction 130
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes 130
Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. 126
Novel neurofibromatosis type 2 mutation presenting with status epilepticus 122
The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples. 119
Consequences of modulating GLI-1 expression in a basal carcinoma cell line. 115
Image analysis in quantitative PCR. An application for the measurement of c-erbB-2 oncogene amplification in DNA from human tumours. 113
The use of COLD-PCR and high-resolution melting analysis improbe the limito f detection of KRAS and BRAF mutations in colorectal cancer 112
Effects of reduced expression of GLI-1 gene in a basal carcinoma cell line. 107
Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. 106
Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population 106
Tacrolimus reduces the expression of GLI-1 by basal cell carcinoma. 98
Partial inhibition of GLI-1 transcription in basal cell carcinoma cells induced by tacrolimus (FK506): an in vitro study. 93
Totale 10.489
Categoria #
all - tutte 28.183
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.183


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 0 0 0 0 0 0 0 51
2021/2022436 19 38 43 14 11 17 14 35 19 14 92 120
2022/20231.184 102 217 48 93 90 209 153 74 131 13 31 23
2023/2024425 12 48 57 29 26 42 14 124 12 17 27 17
2024/20252.763 72 283 195 497 903 369 20 121 97 49 103 54
2025/20262.510 334 365 151 147 379 144 409 118 161 181 50 71
Totale 10.489